Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group
CONCLUSIONS: The combination of dinutuximab with GM-CSF did not significantly improve DCR in recurrent osteosarcoma. Dinutuximab toxicity and pharmacokinetics in adolescent and young adult osteosarcoma patients were similar to younger patients. Other strategies for targeting GD2 in osteosarcoma are being developed.PMID:35809374 | DOI:10.1016/j.ejca.2022.05.035 (Source: Cancer Control)
Source: Cancer Control - July 9, 2022 Category: Cancer & Oncology Authors: Pooja Hingorani Mark Krailo Allen Buxton Paul Hutson Paul M Sondel Mitchell Diccianni Alice Yu Carol D Morris Richard B Womer Brian Crompton R Lor Randall Lisa A Teot Steven G DuBois Katherine A Janeway Richard G Gorlick Michael S Isakoff Source Type: research
Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group
This study evaluated the disease control rate (DCR) in patients with recurrent osteosarcoma treated with the anti-GD2 antibody dinutuximab plus cytokine therapy as compared to historical outcomes. (Source: European Journal of Cancer)
Source: European Journal of Cancer - July 6, 2022 Category: Cancer & Oncology Authors: Pooja Hingorani, Mark Krailo, Allen Buxton, Paul Hutson, Paul M. Sondel, Mitchell Diccianni, Alice Yu, Carol D. Morris, Richard B. Womer, Brian Crompton, R Lor Randall, Lisa A. Teot, Steven G. DuBois, Katherine A. Janeway, Richard G. Gorlick, Michael S. I Tags: Clinical Trial Source Type: research
Saga of monokines in shaping tumour-immune microenvironment: Origin to execution
Cytokine. 2022 Jun 25;157:155948. doi: 10.1016/j.cyto.2022.155948. Online ahead of print.ABSTRACTCellular communication mediated by cytokines is an important mechanism dictating immune responses, their cross talk and final immune output. Cytokines play a major role in dictating the immune outcome to cancer by regulating the events of development, differentiation and activation of innate immune cells. Cytokines are pleiotropic in nature, hence understanding their role individually or as member of network cytokines is critical to delineate their role in tumour immunity. Tumour systemically manipulates the immune system to ev...
Source: Cytokine - June 28, 2022 Category: Molecular Biology Authors: Naveen Challagundla Dhruvi Shah Shivani Yadav Reena Agrawal-Rajput Source Type: research
Saga of monokines in shaping tumour-immune microenvironment: Origin to execution
Cytokine. 2022 Jun 25;157:155948. doi: 10.1016/j.cyto.2022.155948. Online ahead of print.ABSTRACTCellular communication mediated by cytokines is an important mechanism dictating immune responses, their cross talk and final immune output. Cytokines play a major role in dictating the immune outcome to cancer by regulating the events of development, differentiation and activation of innate immune cells. Cytokines are pleiotropic in nature, hence understanding their role individually or as member of network cytokines is critical to delineate their role in tumour immunity. Tumour systemically manipulates the immune system to ev...
Source: Cytokine - June 28, 2022 Category: Molecular Biology Authors: Naveen Challagundla Dhruvi Shah Shivani Yadav Reena Agrawal-Rajput Source Type: research
Immunotherapy: an alternative promising therapeutic approach against cancers
Mol Biol Rep. 2022 Jun 27. doi: 10.1007/s11033-022-07525-8. Online ahead of print.ABSTRACTThe immune system interacts with cancer cells in multiple intricate ways that can shield the host against hyper-proliferation but can also contribute to malignancy. Understanding the protective roles of the immune system in its interaction with cancer cells can help device new and alternate therapeutic strategies. Many immunotherapeutic methodologies, including adaptive cancer therapy, cancer peptide vaccines, monoclonal antibodies, and immune checkpoint treatment, have transformed the traditional cancer treatment landscape. However, ...
Source: Molecular Biology Reports - June 27, 2022 Category: Molecular Biology Authors: Sneh Lata Gupta Srijani Basu Vijay Soni Rishi K Jaiswal Source Type: research
Immunotherapy: an alternative promising therapeutic approach against cancers
Mol Biol Rep. 2022 Jun 27. doi: 10.1007/s11033-022-07525-8. Online ahead of print.ABSTRACTThe immune system interacts with cancer cells in multiple intricate ways that can shield the host against hyper-proliferation but can also contribute to malignancy. Understanding the protective roles of the immune system in its interaction with cancer cells can help device new and alternate therapeutic strategies. Many immunotherapeutic methodologies, including adaptive cancer therapy, cancer peptide vaccines, monoclonal antibodies, and immune checkpoint treatment, have transformed the traditional cancer treatment landscape. However, ...
Source: Molecular Biology Reports - June 27, 2022 Category: Molecular Biology Authors: Sneh Lata Gupta Srijani Basu Vijay Soni Rishi K Jaiswal Source Type: research
Immunotherapy: an alternative promising therapeutic approach against cancers
Mol Biol Rep. 2022 Jun 27. doi: 10.1007/s11033-022-07525-8. Online ahead of print.ABSTRACTThe immune system interacts with cancer cells in multiple intricate ways that can shield the host against hyper-proliferation but can also contribute to malignancy. Understanding the protective roles of the immune system in its interaction with cancer cells can help device new and alternate therapeutic strategies. Many immunotherapeutic methodologies, including adaptive cancer therapy, cancer peptide vaccines, monoclonal antibodies, and immune checkpoint treatment, have transformed the traditional cancer treatment landscape. However, ...
Source: Mol Biol Cell - June 27, 2022 Category: Molecular Biology Authors: Sneh Lata Gupta Srijani Basu Vijay Soni Rishi K Jaiswal Source Type: research
Rare presentation of multiple thromboses in Erdheim-Chester disease: a case-based review
CONCLUSION: We report a rare case of multiple thromboses, embolism, and multiple organ involvement as the main presentation of ECD, suggesting that ECD should be considered in patients presenting with multiple thromboses associated with multisystem damage. We successfully treated our patient with glucocorticoids and interleukin-6 antagonist. This patient's response to treatment suggests that hormone therapy and cytokine/chemokine therapy may be a potential novel treatment for patients with ECD without gene mutations.PMID:35687294 | DOI:10.1007/s12185-022-03393-x (Source: International Journal of Hematology)
Source: International Journal of Hematology - June 10, 2022 Category: Hematology Authors: Yongchang Liu Changpin Huang Xiaohu Meng Xin Fang Xupin Xie Changrong Wang Meiyun Wang Source Type: research
Rare presentation of multiple thromboses in Erdheim-Chester disease: a case-based review
CONCLUSION: We report a rare case of multiple thromboses, embolism, and multiple organ involvement as the main presentation of ECD, suggesting that ECD should be considered in patients presenting with multiple thromboses associated with multisystem damage. We successfully treated our patient with glucocorticoids and interleukin-6 antagonist. This patient's response to treatment suggests that hormone therapy and cytokine/chemokine therapy may be a potential novel treatment for patients with ECD without gene mutations.PMID:35687294 | DOI:10.1007/s12185-022-03393-x (Source: International Journal of Hematology)
Source: International Journal of Hematology - June 10, 2022 Category: Hematology Authors: Yongchang Liu Changpin Huang Xiaohu Meng Xin Fang Xupin Xie Changrong Wang Meiyun Wang Source Type: research
Rare presentation of multiple thromboses in Erdheim-Chester disease: a case-based review
CONCLUSION: We report a rare case of multiple thromboses, embolism, and multiple organ involvement as the main presentation of ECD, suggesting that ECD should be considered in patients presenting with multiple thromboses associated with multisystem damage. We successfully treated our patient with glucocorticoids and interleukin-6 antagonist. This patient's response to treatment suggests that hormone therapy and cytokine/chemokine therapy may be a potential novel treatment for patients with ECD without gene mutations.PMID:35687294 | DOI:10.1007/s12185-022-03393-x (Source: International Journal of Hematology)
Source: International Journal of Hematology - June 10, 2022 Category: Hematology Authors: Yongchang Liu Changpin Huang Xiaohu Meng Xin Fang Xupin Xie Changrong Wang Meiyun Wang Source Type: research
Intratumorally anchored cytokine therapy
. (Source: Expert Opinion on Drug Delivery)
Source: Expert Opinion on Drug Delivery - June 2, 2022 Category: Drugs & Pharmacology Authors: K. Dane Wittrup Howard L. Kaufman Michael M. Schmidt Darrell J. Irvine Source Type: research
Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy
AbstractMacrophages are the most abundant and one of the most critical cells of tumor immunity. They provide a bridge between innate and adaptive immunity through releasing cytokines into the tumor microenvironment (TME). A number of interleukin (IL) cytokine family members is involved in shaping the final phenotype of macrophages toward either a classically-activated pro-inflammatory M1 state with anti-tumor activity or an alternatively-activated anti-inflammatory M2 state with pro-tumor activity. Shaping TME macrophages toward the M1 phenotype or recovering this phenotypic state may offer a promising therapeutic approach...
Source: Cellular Oncology - May 19, 2022 Category: Cancer & Oncology Source Type: research
Histological changes of cervical tumours following < em > Zanthoxylum acanthopodium < /em > DC treatment, and its impact on cytokine expression
Saudi J Biol Sci. 2022 Apr;29(4):2706-2718. doi: 10.1016/j.sjbs.2021.12.065. Epub 2022 Jan 4.ABSTRACTCervical cancer is the second most lethal cancer in Indonesia, behind breast cancer. One of the reasons cancer cells are difficult to treat is that the immune system is sometimes unable to recognise them as foreign. Cytokinin therapy is carried out so that the immune system can strengthen its response to cancer cells, with the aim of slowing or stopping the development of malignant cells. Zanthoxylum acanthopodium DC, also known as andaliman, is an Indonesian herb and a member of the Rutaceae family. It is rich in antioxida...
Source: Cancer Control - May 9, 2022 Category: Cancer & Oncology Authors: Rostime Hermayerni Simanullang Putri Cahaya Situmorang Meriani Herlina None Noradina Bernita Silalahi Sarida Surya Manurung Source Type: research
Shifting role of cytoreductive nephrectomy according to type of systemic therapy: A nationwide cohort study
CONCLUSION: About a quarter patients with mRCC from a nationwide database were treated with CN and ST. CN was beneficial in specific patients with mRCC. Patient selection is crucial for obtaining the benefits of CN.PMID:35450758 | DOI:10.1016/j.asjsur.2022.04.008 (Source: Asian Journal of Surgery)
Source: Asian Journal of Surgery - April 22, 2022 Category: Surgery Authors: Se Young Choi Moon Soo Ha Jeong Woo Lee Jae Hwan Kim Jung Hoon Kim Byung Hoon Chi Jin Wook Kim In Ho Chang Tae-Hyoung Kim Soon Chul Myung Source Type: research
